Aptar’s Nasal Delivery System Powers Phase II Trial for Erectile Dysfunction Treatment
Event summary
- AptarGroup’s proprietary nasal delivery system is being used in LTR Pharma’s Phase II clinical trial for SPONTAN®, an investigational intranasal spray for erectile dysfunction.
- The trial, which began dosing patients in March 2026, evaluates the safety, tolerability, and pharmacokinetic profile of SPONTAN®.
- Aptar Pharma’s multidose nasal spray platform is designed for accurate and consistent dosing of prescription drugs.
- Aptar’s subsidiaries Nanopharm and Noble are providing formulation optimization, analytical services, and human factors support.
The big picture
AptarGroup’s involvement in LTR Pharma’s Phase II trial underscores the growing importance of intranasal drug delivery systems in treating conditions like erectile dysfunction. This collaboration positions Aptar as a key player in advancing innovative, patient-centric therapies, leveraging its proprietary technology and regulatory expertise. The success of SPONTAN® could open new markets for Aptar’s nasal delivery solutions beyond erectile dysfunction.
What we're watching
- Regulatory Pathway
- The pace at which SPONTAN® advances through clinical development and regulatory approvals will determine the commercial viability of the treatment.
- Market Adoption
- Whether Aptar’s nasal delivery system can become a standard in intranasal drug delivery for other pharmaceutical applications.
- Technological Edge
- How Aptar’s formulation and human factors expertise will influence the success of complex intranasal therapies.
Related topics